Clinical Trial DataThe new body composition data from the Phase 2 MOMENTUM trial show lean mass accounted for only 22% of weight lost in pemvidutide-treated patients — less lean mass lost than semaglutide and tirzepatide.
Lipid ReductionsThe company presented new lipid data showing significant reductions in small, dense LDL particles, LDL triglyceride content, and atherogenic lipid species that should translate to cardiovascular benefit over time.
NASH TreatmentSurvodutide showed the best NASH resolution rate seen at 83% and also hit statistical significance on fibrosis which differentiates the GLP-1/glucagon agonists from both the GLP-1 monotherapies and GLP-1/GIP agonists.